Bloomberg 50
Luhan Yang
CO-FOUNDER, EGENESIS
Using Crispr gene-editing technology, EGenesis overcame a major hurdle on the path to animal-to-human organ transplantation, removing 62 viruses that humans are susceptible to from 40 pig embryos.
I’m on a mission to create a world where there are no organ shortages. In the U.S., over 100,000 people are on a waiting list, and only about 20 percent to 30 percent will get one.
The idea of xenotransplantation, or cross-species transplantation, has been around for decades. In the 1990s, there was a huge failure to overcome the compatibility issues that arise with trying to put a pig organ in a human body. Because of public health concerns, the WHO and USDA shut down all clinical trials, and the field has been silent.
There are two major barriers to xenotransplantation using pigs. One is viruses known as PERVs. PERVs reside in the pig genome and can integrate into the human genome. In 2015 we showed that we could use Crispr gene editing to eradicate 62 PERVs in pig cells. But one of the biggest questions was whether the PERVs played a crucial function in the pig. For the first time, in 2017, we answered the question: They’re dispensable.
It took hundreds of trials to get to a viable, “PERV-inactive” pig. Too many edits to a pig’s cells will stress out the cells, leading them to essentially commit suicide. We created a chemical cocktail to tell the cell, “It’s OK, don’t worry.” The first pig was born in China in March. We’re testing them to see if they have normal physiology and can produce offspring that preserve the genetic modification.
The other barrier is that, even though we know how to remove PERVs, there’s still the possibility that a human host could reject a pig organ. It’s still early days. We’re talking with the FDA about how to test our organs’ compatibility. We’ve just finished raising a $38 million Series A, and while we don’t have a clear path to market, we always keep our goal in mind: to deliver an organ. We’re not doing science for intellectual purposes.
—As told to Caroline Chen
Read full article here.